U.S. Markets close in 1 hr 14 mins

Should You Be Tempted To Sell Nu Skin Enterprises Inc (NYSE:NUS) At Its Current PE Ratio?

I am writing today to help inform people who are new to the stock market and want to learn about the link between company’s fundamentals and stock market performance.

Nu Skin Enterprises Inc (NYSE:NUS) is trading with a trailing P/E of 25.9, which is higher than the industry average of 21.7. Though this might seem to be a negative, you might change your mind after I explain the assumptions behind the P/E ratio. In this article, I will deconstruct the P/E ratio and highlight what you need to be careful of when using the P/E ratio.

Check out our latest analysis for Nu Skin Enterprises

Breaking down the Price-Earnings ratio

NYSE:NUS PE PEG Gauge October 17th 18

P/E is a popular ratio used for relative valuation. By comparing a stock’s price per share to its earnings per share, we are able to see how much investors are paying for each dollar of the company’s earnings.

P/E Calculation for NUS

Price-Earnings Ratio = Price per share ÷ Earnings per share

NUS Price-Earnings Ratio = $70.51 ÷ $2.721 = 25.9x

The P/E ratio isn’t a metric you view in isolation and only becomes useful when you compare it against other similar companies. Our goal is to compare the stock’s P/E ratio to the average of companies that have similar attributes to NUS, such as company lifetime and products sold. A common peer group is companies that exist in the same industry, which is what I use. Since NUS’s P/E of 25.9 is higher than its industry peers (21.7), it means that investors are paying more for each dollar of NUS’s earnings. This multiple is a median of profitable companies of 15 Personal Products companies in US including Tauriga Sciences, Shineco and Spring Pharmaceutical Group. You could also say that the market is suggesting that NUS is a stronger business than the average comparable company.

Assumptions to watch out for

Before you jump to conclusions it is important to realise that there are assumptions in this analysis. The first is that our “similar companies” are actually similar to NUS. If not, the difference in P/E might be a result of other factors. For example, Nu Skin Enterprises Inc could be growing more quickly than the companies we’re comparing it with. In that case it would deserve a higher P/E ratio. Of course, it is possible that the stocks we are comparing with NUS are not fairly valued. So while we can reasonably surmise that it is optimistically valued relative to a peer group, it might be fairly valued, if the peer group is undervalued.

What this means for you:

If your personal research into the stock confirms what the P/E ratio is telling you, it might be a good time to rebalance your portfolio and reduce your holdings in NUS. But keep in mind that the usefulness of relative valuation depends on whether you are comfortable with making the assumptions I mentioned above. Remember that basing your investment decision off one metric alone is certainly not sufficient. There are many things I have not taken into account in this article and the PE ratio is very one-dimensional. If you have not done so already, I urge you to complete your research by taking a look at the following:

  1. Future Outlook: What are well-informed industry analysts predicting for NUS’s future growth? Take a look at our free research report of analyst consensus for NUS’s outlook.
  2. Past Track Record: Has NUS been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of NUS’s historicals for more clarity.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.